Masimo Reports Third Quarter 2016 Financial Results

Q3 2016 Highlights (compared to Q3 2015):

  • Total revenue, including royalties, rose 9.9% to $167.6 million
  • Product revenue rose 10.8% to $160.3 million
  • Masimo rainbow® revenue rose 5.0% to $18.0 million
  • 45,800 SET® and rainbow® SET® oximeters were shipped
  • GAAP net income of $27.8 million, or $0.52 per diluted share versus $19.3 million, or $0.36 per diluted share in the year-ago period

IRVINE, Calif.--()--Masimo (NASDAQ: MASI) today announced its financial results for the third quarter ended October 1, 2016.

Third quarter 2016 product revenues rose 10.8% to $160.3 million, compared to $144.6 million for the third quarter of fiscal year 2015, and total revenue, including royalties, rose 9.9% to $167.6 million, up from $152.6 million for the third quarter of fiscal year 2015.

The company’s worldwide direct product revenue in the third quarter of 2016 rose by 14.3% compared to the same period in 2015 and represented 85.7% of product revenue. OEM sales, which accounted for 14.3% of product revenue, declined by 6.1% to $22.9 million in the third quarter of 2016 compared to the same period in 2015. Revenue from sales of Masimo rainbow® products rose by 5.0% to $18.0 million in the third quarter of 2016, compared to the same period in 2015.

GAAP net income for the third quarter of 2016 was $27.8 million, or $0.52 per diluted share, compared to GAAP net income of $19.3 million, or $0.36 per diluted share, in the third quarter of 2015. Included in the third quarter 2016 earnings per share was $0.05 per diluted share related to the impact of the new stock option gain accounting rule, ASU 2016-09. During the third quarter of 2016, the company shipped approximately 45,800 SET® Pulse Oximeters and rainbow SET Pulse CO-Oximeters, excluding handheld units. Masimo estimates its worldwide installed base as of October 1, 2016 to be 1,482,000 units, up 6.6% from 1,390,000 units as of October 3, 2015.

Joe Kiani, Chairman and Chief Executive Officer of Masimo, said, “We are happy to report third quarter product revenues and earnings per share that exceeded our projections. Product revenues benefited from continued strength in our consumable business and new product sales. We continue to believe that these results are due to both our superior technologies and the increasing awareness of both hospitals and clinicians who recognize that our technologies can improve patient care and reduce the cost of delivering that care. Because of our strong Q3 results and the increased demand we continue to see for our products, I am happy that we will be able to once again increase our financial guidance for the year.”

As of October 1, 2016, total cash and cash investments were $126.0 million compared to $132.3 million as of January 2, 2016. During the nine month period ended October 1, 2016, the company generated $87.8 million in cash from operations and received $26.1 million in proceeds from stock option exercises. During the same nine month period, the company repurchased 1.5 million shares at total cost of $63.4 million and made $77.5 million in repayments on the Company’s line-of-credit.

2016 Financial Guidance

Masimo today is updating its 2016 financial guidance. Masimo now expects fiscal 2016 total revenues to be approximately $692 million, up from $689 million. Total fiscal 2016 product revenues are now expected to be approximately $661 million, up from $658 million, while royalty revenues expectations remain unchanged at approximately $31 million. Masimo now also expects its fiscal 2016 GAAP earnings per diluted share to be $2.13, up from $2.01. Masimo will provide additional financial information during the conference call today. Each of the components of Masimo’s guidance set forth above is an estimate only and actual performance could differ.

Conference Call

Masimo will hold a conference call today at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results. A live webcast of the call will be available online from the investor relations page of the company’s website at The dial-in numbers are (888) 520-7182 for domestic callers and +1 (706) 758-3929 for international callers. The reservation code for both dial-in numbers is 1397285. After the live webcast, the call will be available on Masimo’s website through November 16, 2016. In addition, a telephonic replay of the call will be available through November 30, 2016. The replay dial-in numbers are (855) 859-2056 for domestic callers and +1 (404) 537-3406 for international callers. Please use reservation code 1397285.

About Masimo

Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications. In 1995, the company debuted Masimo SET® Measure-through Motion and Low Perfusion pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. Masimo SET® is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and more recently, Pleth Variability Index (PVI®) and Oxygen Reserve Index (ORI), in addition to SpO2, pulse rate and perfusion index (PI). In 2014, Masimo introduced Root®, an intuitive patient monitoring and connectivity platform with the Masimo Open Connect (MOC-9) interface. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7 wearable patient monitor and the MightySat fingertip pulse oximeter. Additional information about Masimo and its products may be found at

Forward-Looking Statements

All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements including, in particular, the statements about our expectations for full fiscal year 2016 total, product and royalty revenues and GAAP earnings per diluted share; demand for our products; anticipated revenue and earnings growth; our financial condition, results of operations and business generally; expectations regarding our ability to design and deliver innovative new noninvasive technologies and reduce the cost of care; and demand for our technologies. These forward-looking statements are based on management’s current expectations and beliefs and are subject to uncertainties and factors, all of which are difficult to predict and many of which are beyond our control and could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to, those related to: our dependence on Masimo SET® and Masimo rainbow SET products and technologies for substantially all of our revenue; any failure in protecting our intellectual property exposure to competitors’ assertions of intellectual property claims; the highly competitive nature of the markets in which we sell our products and technologies; any failure to continue developing innovative products and technologies; the lack of acceptance of any of our current or future products and technologies; obtaining regulatory approval of our current and future products and technologies; the risk that the implementation of our international realignment will not continue to produce anticipated operational and financial benefits, including a continued lower effective tax rate; the loss of our customers; the failure to retain and recruit senior management; product liability claims exposure; a failure to obtain expected returns from the amount of intangible assets we have recorded; the maintenance of our brand; the amount and type of equity awards that we may grant to employees and service providers in the future; our ongoing litigation and related matters; and other factors discussed in the “Risk Factors” section of our most recent periodic reports filed with the Securities and Exchange Commission (“SEC”), including our most recent Form 10-K and Form 10-Q, all of which you may obtain for free on the SEC’s website at Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise. We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI and ORI are trademarks or registered trademarks of Masimo Corporation.

(unaudited, in thousands)
  October 1,   January 2,
  2016     2016  
Current assets
Cash and cash equivalents $ 125,988 $ 132,317
Accounts receivable, net of allowance for doubtful accounts 94,374 80,960
Inventories 67,047 62,038
Other current assets   37,213     23,827  
Total current assets 324,622 299,142
Deferred cost of goods sold 83,066 71,718
Property and equipment, net 133,150 132,466
Intangible assets, net 29,816 27,556
Goodwill 20,252 20,394
Deferred tax assets 39,403 44,320
Other non-current assets   9,144     6,139  
Total assets $ 639,453   $ 601,735  
Current liabilities
Accounts payable $ 32,232 $ 25,865
Accrued compensation 37,099 38,415
Accrued and other current liabilities 42,867 47,073
Deferred revenue   32,137     21,280  
Total current liabilities 144,335 132,633
Long term debt 152,500 185,071
Other non-current liabilities   9,431     8,319  
Total liabilities 306,266 326,023
Commitments and contingencies
Masimo Corporation stockholders’ equity:
Common stock 50 50
Treasury stock (404,276 ) (340,873 )
Additional paid-in capital 368,501 332,417
Accumulated other comprehensive loss (5,019 ) (4,739 )
Retained earnings   373,931     288,560  
Total Masimo Corporation stockholders’ equity 333,187 275,415
Noncontrolling interest       297  
Total equity   333,187     275,712  
Total liabilities and equity $ 639,453   $ 601,735  
(unaudited, in thousands, except per share amounts)
  Three Months Ended   Nine Months Ended
October 1,   October 3, October 1,   October 3,
  2016     2015   2016   2015  
Product $ 160,286 $ 144,603 $ 488,183 $ 439,572
Royalty   7,335     7,972     23,241   23,266  
Total revenue 167,621 152,575 511,424 462,838
Cost of goods sold   57,499     50,343     171,954   154,600  
Gross profit 110,122 102,232 339,470 308,238
Operating expenses:
Selling, general and administrative 57,845 59,607 184,244 182,072
Research and development   15,673     14,485     44,856   42,808  
Total operating expenses   73,518     74,092     229,100   224,880  
Operating income 36,604 28,140 110,370 83,358
Non-operating income (expense)   (546 )   (1,050 )   423   (2,022 )
Income before provision for income taxes 36,058 27,090 110,793 81,336
Provision for income taxes   8,285     9,161     25,420   24,889  
Net income including noncontrolling interest 27,773 17,929 85,373 56,447
Net loss attributable to the noncontrolling interest       1,396       2,752  
Net income attributable to Masimo Corporation stockholders $ 27,773   $ 19,325   $ 85,373 $ 59,199  
Net income per share attributable to Masimo Corporation stockholders:
Basic $ 0.56   $ 0.38   $ 1.73 $ 1.15  
Diluted $ 0.52   $ 0.36   $ 1.62 $ 1.10  
Weighted-average shares used in per share calculations:
Basic   49,477     50,974     49,386   51,653  
Diluted   53,565     53,686     52,837   53,946  

The following table presents details of the stock-based compensation expense that is included in each functional line item in the condensed consolidated statements of operations (in thousands):

Three Months Ended Nine Months Ended
October 1, October 3, October 1, October 3,
  2016     2015   2016   2015  
Cost of goods sold $ 122 $ 79 $ 269 $ 270
Selling, general and administrative 2,540 1,985 7,314 6,052
Research and development   827     639     2,110   1,810  
Total $ 3,489   $ 2,703   $ 9,693 $ 8,132  
(unaudited, in thousands)
  Nine Months Ended
October 1,   October 3,
  2016     2015  
Cash flows from operating activities:
Net income including noncontrolling interest $ 85,373 $ 56,447
Adjustments to reconcile net income including noncontrolling interest to net cash provided by operating activities:
Depreciation and amortization 12,355 11,603
Stock-based compensation 9,693 8,132
Loss on disposal of property, equipment and intangibles 478 423
Gain on deconsolidation of variable interest entity (273 )
Provision for doubtful accounts 127 506
Provision for deferred income taxes 5,002
Changes in operating assets and liabilities:
Increase in accounts receivable (13,525 ) (5,048 )
Increase in inventories (5,092 ) (3,755 )
Increase in other current assets (12,911 ) (5,003 )
Increase in deferred cost of goods sold (11,278 ) (1,007 )
Increase in other non-current assets (2,317 ) (3,661 )
Increase (decrease) in accounts payable 9,232 (4,179 )
Decrease in accounts payable to related party (1,092 )
Decrease in accrued compensation (810 ) (1,436 )
Increase (decrease) in accrued liabilities 862 (482 )
Increase in deferred revenue 10,857 3,465
Increase (decrease) in other non-current liabilities   1,149     (272 )
Net cash provided by operating activities   87,830     55,733  
Cash flows from investing activities:
Purchases of property and equipment, net (13,697 ) (40,520 )
Increase in intangible assets (3,969 ) (3,486 )
Reduction in cash resulting from deconsolidation of variable interest entity   (763 )    
Net cash used in investing activities   (18,429 )   (44,006 )
Cash flows from financing activities:
Borrowings under line of credit 45,000 107,500
Repayments on line of credit (77,500 ) (42,500 )
Debt issuance costs (621 )
Repayments of capital lease obligations (72 ) (81 )
Proceeds from issuance of common stock 26,063 24,942
Payroll tax withholdings on behalf of employees for stock options (472 )
Repurchases of common stock (68,218 ) (130,157 )
Issuance of equity by noncontrolling interest, net of equity issued       4  
Net cash used in financing activities   (75,348 )   (40,764 )
Effect of foreign currency exchange rates on cash   (382 )   (1,835 )
Net decrease in cash and cash equivalents (6,329 ) (30,872 )
Cash and cash equivalents at beginning of period   132,317     134,453  
Cash and cash equivalents at end of period $ 125,988   $ 103,581  


Investor Contact:
Eli Kammerman
(949) 297-7077
Media Contact:
Irene Paigah
(858) 859-7001


Investor Contact:
Eli Kammerman
(949) 297-7077
Media Contact:
Irene Paigah
(858) 859-7001